ReviewInternational journal of women's dermatology2021
Urticarial vasculitis.
Review in International journal of women's dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 0 citations in OpenAlex.
- Angioedema: a rare manifestation of Henoch-Schönlein purpura.BMJ case reports · 2026Article
- Atypical Persistent Pruritic Hyperpigmented Plaques in Adult-Onset Still's Disease: A Case Report From Uganda.Clinical case reports · 2026Article
- Treatment Challenges in Refractory Urticarial Vasculitis.Clinical, cosmetic and investigational dermatology · 2026Article
- Clinical Profile of Patients with Urticarial Vasculitis in China: A Retrospective of 142 Cases.Journal of inflammation research · 2026Article
- Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations.Virology journal · 2025Review
- Article
- Challenging Clinical Therapeutic Approach to Urticarial Vasculitis: A Case Series.Journal of clinical medicine · 2025Article
- Article
- Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus.American journal of clinical dermatology · 2025Review
- Article
- A Case of Hypocomplementemic Urticarial Vasculitis Syndrome With Severe Renal and Gastrointestinal Involvement.Cureus · 2024Article
- Lung Involvement in Pulmonary Vasculitis: A Radiological Review.Diagnostics (Basel, Switzerland) · 2024Review
- Breaking Out of the Hive: A Case Report on Hypocomplementemic Urticarial Vasculitis Syndrome.Cureus · 2024Article
- Article
- A case of urticarial vasculitis associated with atezolizumab.JAAD case reports · 2024Article
- Urticaria: A Narrative Overview of Differential Diagnosis.Biomedicines · 2023Review
- Article
- Erythema Multiforme Following Hepatitis A and Pneumococcal Vaccinations.The Yale journal of biology and medicine · 2022Article
- SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.Dermatologic therapy · 2022Review
- [Update on etiopathogenesis of small vessel vasculitis].Zeitschrift fur Rheumatologie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.